Absolutely keep an eye on that long term outlook. Some of the...

First 98 Last

Share
Profile

Follow
Robcc66

367 Posts.

13

22/09/17

12:58

Post #: 27395598
Share

Originally posted by Bron ↑

Hi Andy, Agreed! This stock offers some very good short term gains, as we wait to see what share prices will fetch over the medium to long term. I see a very good run for us ahead, well over a decade, and I like the idea of a 15 year supercycle in lithium, as one of the articles I was reading, alluded to. Could be longer... who knows? I'm not keen to move money around too much in this sector, as I really can't complain about the gains made here over the past year. The shorters are everywhere, and we can't do anything about that. As we have read, they had been active in the lithium major companies, however, I understand, not as much there now. However, their attention has been on the lithium juniors, and the gains being achieved in the lithium ETF. However, the time will come when the shorts will run out of luck, and there is the possibility of many of them getting cooked. We all have our personal strategies, and risk profiles, for making what we believe to be outstanding gains. From an investor's perspective, Galaxy is very cheap at current prices. Don't let the big money take all the winnings. GLTA

Expand

Absolutely keep an eye on that long term outlook. Some of the projections on the weekly charts for these Lithiums are almost scary but even though you may fiddle in and out on the corrections, sometimes profitable, sometimes not, key is to be nicely settled in on the big runs.

GXY Price at posting: $2.50 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

SKS

SKS secures $20M for extension works on Melbourne data centre

BOE

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s

EBR

EBR Systems' heart pacing device on-target to reach the US market